Introduction
Bacterial resistance to antibiotics is on the rise and represents a critical unmet medical need. 1 -3 In addition, there is a paucity of new antibiotics in the development pipeline, with the few agents under development often being improved derivatives of marketed products that are generally only partially effective against existing resistance mechanisms. Therefore, there is an urgent need to identify novel antibacterial targets and leads with new mechanisms of action.
GSK1322322, the first in a new class of antibiotics, is a potent inhibitor of peptide deformylase (PDF) discovered by a combination of structure-based drug design and iterative medicinal chemistry ( Figure 1) . 4 PDF is an essential bacterial enzyme required for protein maturation. 5 Because PDF is not required by mammalian cells and is to date clinically unexploited, development of agents against this protein is an attractive proposition. GSK1322322 shows no target-based cross-resistance with currently used agents and is fully active against pathogens resistant to multiple classes of existing antibiotics. 6 GSK1322322 demonstrated potent in vitro and in vivo activity against multidrug-resistant respiratory and skin pathogens, including methicillin-resistant Staphylococcus aureus. 6 -8 In vitro, GSK1322322 exhibits a potent sub-MIC effect for most strains of S. aureus, inhibiting growth in vitro for 6-8 h at concentrations well below the MIC. 9, 10 In addition, potent in vivo activity of GSK1322322 against rodent respiratory tract infection and skin and soft tissue infection models has also been demonstrated. In a single-dose, pharmacokinetic (PK), first-time-in-human, Phase 1 study in healthy volunteers, GSK1322322 was administered as a powder-in-bottle formulation and demonstrated a favourable PK profile. 8 In this two-part, Phase 1 study, the objective of Part A was to investigate the safety, tolerability and PK of GSK1322322 following single and repeat dosing with dose escalation from 500 to 1500 mg twice daily in healthy adult volunteers (18 -65 years of age); the objective of Part B was to assess the safety, tolerability and PK of GSK1322322 following single and repeat dosing of 1000 mg twice daily in healthy elderly volunteers (.65 years of age).
Patients and methods

Study design and population
This was a randomized, double-blind, placebo-controlled, single-and repeat-dose, dose-escalation, Phase 1 trial of healthy volunteers (GlaxoSmithKline Clinical Study Register; study identifier: PDF112668). Adult volunteers who were in generally good health with no clinically relevant abnormalities as determined by medical history, physical exam, laboratory tests and cardiac monitoring were eligible for the trial. Volunteers had a body mass index of 18.5 -29.9 kg/m 2 , inclusive. Female volunteers were eligible to be enrolled if they were of nonchildbearing potential and were excluded if they were lactating or pregnant, as determined by positive human chorionic gonadotropin test at screening or prior to dosing. Volunteers were excluded from the study if they met one of the following conditions: a positive result for pre-study screening of alcohol and drugs of abuse, including amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines; a positive hepatitis B surface antigen or hepatitis C antibody result within 3 months of screening; a positive test result for HIV antibody; use of any investigational drug within 30 days, five half-lives or twice the duration of the biological effect of the investigational drug (whichever was longer) before the day of dosing; or exposure to more than four new chemical entities within 12 months before the day of dosing. All volunteers provided written informed consent. The study was approved by an institutional review board (Bellberry Human Research Ethics Committee, Dulwich, South Australia) and was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.
Overall, five GSK1322322-treated cohorts were planned for this two-part study. Part A was planned with four cohorts to study the single-and repeat-dose safety, tolerability and PK of GSK1322322 with dose escalation from 500 to 1500 mg (i.e. Cohorts A-D) in adult volunteers aged 18-65 years. The study was designed to administer GSK1322322 to eight volunteers and placebo to two volunteers at each dose level of 500, 750, 1000 and 1500 mg twice daily (i.e. Cohorts A, B, C and D, respectively). In addition, volunteers in one cohort (Cohort C) received midazolam (5 mg) as a metabolic probe drug to understand the effect of GSK1322322 on cytochrome P450 3A activity. Part B was planned with one cohort (Cohort E, 1000 mg twice daily) to study the safety, tolerability and PK of single-and repeat-dose GSK1322322 in elderly volunteers aged .65 years. This cohort was planned to comprise eight and four volunteers receiving GSK1322322 and placebo, respectively.
Volunteers were admitted to the study unit the day before drug administration and discharged after all study procedures were completed on day 14. Volunteers were assigned to study treatment in accordance with the randomization schedule generated by Discovery Biometrics before the start of the study using validated internal software. Each volunteer scheduled to receive study drug received a treatment allocation number when randomized, which indicated whether the individual was to receive the scheduled dose of GSK1322322 or placebo. Volunteers received a single morning (AM) dose of GSK1322322 or placebo orally on day 1, no dosing on day 2 and twice-daily dosing on days 3 -12. The AM dose of GSK1322322 and placebo was administered following an overnight fast of ≥10 h. Volunteers were orally administered a powder-in-bottle formulation as a suspension of GSK1322322 or microcrystalline cellulose for placebo. Volunteers in Cohort C were also administered a single dose of 5 mg of midazolam on the day before study drug administration, and 5 mg of midazolam was coadministered with the morning dose of GSK1322322 or placebo on days 1 and 12. Volunteers in all cohorts returned for follow-up visits at 7 -10 and 28 days after their last dose of study medication.
PK assessments
Blood samples to measure plasma GSK1322322 concentrations were collected pre-dose (within 15 min before dosing) and for a 48 h period (i.e. at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36 and 48 h) after dosing on day 1. On days 5, 6, 10 and 11, blood samples were collected pre-dose (within 15 min before AM dosing). On days 7 and 12, for AM dosing, blood samples were collected pre-dose (within 15 min before AM dosing) and for a 12 h period (i.e. at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8 and 12 h) post-dose. On day 12, for evening (PM) dosing, blood samples were collected for a 72 h period (i.e. at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 36, 48 and 72 h) after the PM dose. Volunteers emptied their bladder 20 min before dosing and 20 mL urine samples were collected at baseline on day 1 (0 h) for reference. On day 12, urine was collected over the following intervals: 0-12 h after the AM dose and 0-12 h after the PM dose.
Plasma and urine GSK1322322 concentrations were determined by Worldwide Bioanalysis (GlaxoSmithKline, King of Prussia, PA, USA) using HPLC with tandem mass spectrometry with a validated range of 5 -5000 ng/mL GSK1322322 concentration in human plasma. The assay for GSK1322322 concentration in human urine was validated over a range of 0.5-500 mg/L. PK analyses of plasma GSK1322322 concentration-time data were conducted using non . The accumulation ratio (Ro) was calculated as the ratio of the AUC from time 0 -12 h after AM dosing [AUC 0 -12 (AM)] on days 7 and 12 to the AUC from time 0 -12 h (AUC 0 -12 ) on day 1 for each volunteer. The time invariance ratio (Rs) was calculated as the ratio of the AUC over two dosing intervals (AUC 0 -24 ) on day 12 to two times the AUC 0 -1 on day 1 for each volunteer. For urine PK analysis, the total amount of GSK1322322 excreted (Ae) and CL R were assessed. From the GSK1322322 urine data, the Ae was determined after repeat dosing at steady-state on day 12 and was calculated as the product of the concentration in urine and the urine weight (assuming a urine density of 1 g/mL). Naderer et al.
Safety assessments
Safety was assessed by the evaluation of reported and observed adverse events (AEs), vital sign measurements, electrocardiograms (ECGs) and clinical laboratory tests (i.e. chemistry, haematology and urinalysis). Twelve-lead ECGs were obtained as three measurements taken pre-dose on day 1. The ECGs were centrally read by Quintiles Cardiac Safety Services (Mumbai, India). Holter monitoring was performed for 24 h at screening.
Statistical analyses
Baseline and demographic characteristics, safety data and PK parameters were summarized using descriptive statistics. All PK parameters were log e transformed with the exception of T max . The dose proportionality of GSK1322322 PK parameters for single-dose (AUC 0 -1 and C max ) and repeat-dose [AUC over two dosing intervals (AUC 0 -24 ), C max (AM) and C max (PM)] administration was assessed using the power model: y¼a . dose b (where y denotes the PK parameter being analysed, a depends on the random error and the exponent b was estimated by regressing the log e -transformed PK parameter on the log e -transformed dose). Dose proportionality required b to be at unity for dose-dependent parameters, whilst the corresponding 90% CI was used to quantify the degree of proportionality or non-proportionality. For steady-state assessment, the plasma GSK1322322 pre-morning dose concentration values obtained between days 5 and 12 of the repeat-dose phase were plotted and summarized. A mixed-effects model with individual as a random effect was performed by dose on the log e -transformed C t . Day was treated as a continuous variable in the model. The 90% CI of the slope of the linear regression was calculated for each dose group. For the assessment of Ro and Rs, analyses of variance with terms for volunteer as a random effect and day as a fixed effect were performed on the log e -transformed AUC with day treated as a categorical variable. Reference points were AUC 0 -12 on day 1 for Ro and two times the AUC 0 -1 on day 1 for Rs.
The potential effect of age on the single-dose and steady-state PK of GSK1322322 at 1000 mg was determined by comparing the AUC and C max obtained from elderly healthy volunteers with those from healthy adult volunteers. Following log e transformation, AUC 0 -1 on day 1 and AUC 0 -24 over two dosing intervals on day 12 were separately analysed using analysis of variance with age as a fixed effect.
Results
A total of 52 volunteers enrolled in the study between May and September 2009: 40 in Part A and 12 in Part B (Figure 2 ). Of the 40 volunteers included in Part A, 8 volunteers in each of four treatment cohorts were randomized to receive 500, 750, 1000 or 1500 mg of GSK1322322 and 8 volunteers were randomized to placebo. Three volunteers in Part A (one each in Cohorts A, B and C) of the study withdrew because of AEs. Of the 12 elderly volunteers included in Part B, 4 received placebo and 8 received 1000 mg of GSK1322322. All volunteers in Part B completed the study as planned. The majority of volunteers were white (85%) and male (87%; Table 1 ). In Parts A and B, the age of the volunteers ranged from 20 to 53 and from 65 to 74 years, respectively.
PK
Following single-dose administration (day 1) of 500-1500 mg of GSK1322322 to volunteers, the drug was readily absorbed with a median T max of 0.5 h and was eliminated with mean t 1 2 values ranging from 5.3 to 6.8 h across doses in both Parts A and B of the study (Table 2 and Figure 3 ). With repeat dosing (days 7 and 12) of 500 -1500 mg of GSK1322322, the median T max was 0.5 -1 h after morning and evening doses across all cohorts in both Parts A and B of the study. After PM dosing on day 12, GSK1322322 was eliminated with a mean t 1 2 of 5-6 h at low doses (500 and 750 mg) and a slightly longer mean t 1 2 ( 8 -9 h) at higher doses (1000 and 1500 mg). The mean C max and AUC values increased with increasing dose. The AUC, C max and T max values were similar between the morning and evening dosings of GSK1322322, indicating no diurnal variation in GSK1322322 PK. In addition, although the mean plasma GSK1322322 trough concentrations (C t ) increased with increasing dose following multiple dosing, the mean C t values remained generally constant, with clustering between 0.07 and 0.5 mg/L from day 5 to day 13 that indicated that steady-state was achieved within 2 days of repeat dosing (i.e. on day 5; Figure 4 ). The slope estimates of C t values versus time were generally close to zero, confirming the achievement of steady-state by day 5 ( Table 3) .
The results of the dose-proportionality assessment indicated that after a single oral dose of GSK1322322, the point estimates of the slopes for AUC 0 -1 and C max were around unity (i.e. 1.0), suggesting that the PK parameters of GSK1322322 were approximately dose proportional from 500 to 1500 mg (Table 4) . After repeat dosing, AUC 0 -24 values over two dosing intervals at steady-state on day 12 were slightly greater than dose proportional (slope of 1.29). This may be due to the slightly longer t 1 2 (i.e. 8 -9 h) with repeat dosing as compared with the single-dose t 1 2 (i.e. 5 -7 h) at higher doses (1000 and 1500 mg). Dose proportionality assessment results for C max at steady-state differed slightly between morning and evening doses. C max (AM) values were proportional to the GSK1322322 dose; however, C max (PM) values were slightly more than proportional to dose.
At low doses (i.e. 500 and 750 mg), GSK1322322 followed linear PK after repeat dosing, as the point estimates of Rs were close to 1 and the 90% CI contained 1 ( Table 5 ). The Ro was minimal (i.e. 10% -21%), which is consistent with its t 1 2 of 5-6 h and the dosing frequency. However, at higher doses (i.e. 1000 and 1500 mg) a small degree of time-dependent nonlinearity was observed, with Rs .1 and Ro being slightly higher (i.e. 13% -51%) than expected, which was probably due to the longer t 1 2 observed with repeat dosing (i.e. 8 -9 h) compared with that of the single dose (i.e. 5 -7 h) at these dose levels.
There was no effect of midazolam on the single-dose or repeat-dose GSK1322322 PK profile in Cohort C volunteers (1000 mg of GSK1322322). The effect of GSK1322322 on the plasma midazolam PK profile is beyond the scope of this article and therefore will be reported elsewhere. In brief, there was a significant interaction between single and repeat doses of GSK1322322 and inhibition of cytochrome P450 3A4/5, resulting in reduced midazolam clearance.
The effect of age on the GSK1322322 PK profile was assessed by comparing the AUC, C max and T max values for dosing of GSK1322322 at 1000 mg in elderly volunteers (.65 years of age; Cohort E) versus adult volunteers (18 -65 years of age; Cohort C). When comparing the AUC [i.e. AUC 0 -24 (over two dosing intervals on day 12) and AUC 0 -1 (single dose)] and C max of GSK1322322 between these two cohorts, the point estimates were close to 1 and the 90% CI included 1, indicating that age had no effect on the systemic exposure of GSK1322322 (Table 6 ).
Repeat-dose safety and pharmacokinetics of GSK1322322
Most of these PK parameters exhibited moderate within-volunteer variability, with the exception of C max (AM), which tended to have a higher variation than the other parameters.
The amount of GSK1322322 excreted in the urine over two dosing intervals at steady-state (Ae 0 -24 ) increased as the dose increased (Table 7) . On the basis of the mean Ae 0 -24 , the fraction Naderer et al.
of intact GSK1322322 recovered in the urine in 24 h ranged from 22% to 25% of the total administered daily dose. The mean CL R of GSK1322322 at steady-state was generally consistent across all regimens, including that for Cohort E (elderly volunteers), and ranged from 6 to 9 L/h.
Safety
GSK1322322 doses of 500-1500 mg, given over 10 days of continuous dosing, were generally well tolerated in this study. The most frequently reported AEs in the study (both Parts A and B) included headache, somnolence, upper respiratory tract infection, musculoskeletal pain, dyspepsia and nausea (Table 8 ). All AEs were mild to moderate in intensity.
No trends in AEs related to dose were observed. Somnolence, a known side effect of midazolam, was only reported when midazolam was given alone or concomitantly with GSK1322322 (Cohort C). No non-fatal or fatal serious AEs were reported in this study; however, three volunteers withdrew from the study because of AEs. One volunteer receiving 750 mg of GSK1322322 (Cohort B) withdrew on day 11 because of diffuse maculopapular rash that developed after the day 10 PM dose. This rash was considered by the investigator to be related to the study drug and resolved in 6 days. Two volunteers had mildly elevated liver enzymes that met protocol-defined volunteer stopping criteria (i.e. at least three times the upper limit of normal), one receiving 500 mg of GSK1322322 (Cohort A) and the other receiving 1000 mg of GSK1322322 (Cohort C). These AEs were also considered by the investigator to be related to the study drug. The volunteer in Cohort A had a maximal elevated alanine aminotransferase (ALT) value of 90 IU/L (i.e. three times the upper limit of normal) on day 11 that resolved in 11 days. Similarly, the volunteer in Cohort C had an ALT value of 163 IU/L on day 13 that resolved in 18 days. However, these ALT changes were not associated with clinical symptoms or changes in bilirubin. Repeat-dose safety and pharmacokinetics of GSK1322322 No significant trends or changes from baseline in vital signs, chemistry and haematology data were observed. Apart from the two volunteers on GSK1322322 that had elevated ALT that met protocol-defined subject stopping criteria and withdrew from the study, two more volunteers on active treatment and one volunteer on placebo had elevations in ALT. No significant trends or changes from baseline in ECG data were observed. Although no volunteers had QT duration corrected for heart rate by Bazett's formula (QTcB) values that were .480 ms, eight volunteers had QTcB values of potential clinical importance (i.e. values .450 ms or representing a change from baseline of .60 ms; six adults and one elderly volunteer on GSK1322322, and one adult on placebo).
Discussion
This two-part, Phase 1 study evaluated the safety, tolerability and PK of GSK1322322 at doses of 500-1500 mg in healthy adult (aged 18-65 years) and elderly (aged .65 years) volunteers following single and multiple oral dosing. GSK1322322 at doses of 500-1500 mg, given over 10 days of continuous dosing, was generally well tolerated, with no serious AEs occurring during the study. Three volunteers in Part A withdrew from the study because of AEs; one volunteer had a diffuse maculopapular rash and two volunteers had elevated liver enzymes. Naderer et al.
These AEs resolved after study drug discontinuation and were considered by the investigator to be mild and related to the study drug. GSK1322322 dose selection in this study was based on animal models simulating the human serum concentrations necessary for potent antibacterial activity 11 and PK results from the firsttime-in-human, single-dose study. 8 The single-and repeat-dose PK of GSK1322322 evaluated in the current study were, in general, consistent with those observed in the first-time-in-human study that used the same powder-in-bottle formulation for GSK1322322. After a single dose, GSK1322322 C max and AUC 0 -1 were dose proportional from 500 to 1500 mg. However, after repeat doses, AUC at steady-state was slightly more than dose proportional, perhaps because of slightly higher than expected accumulations of GSK1322322 (as a result of the somewhat longer t 1 2 with repeat dosing compared with that of single dosing) at higher doses (i.e. 1000 and 1500 mg).
Physiological changes in the elderly often alter the PK of drugs, necessitating dose adjustments for the therapeutics used to treat this population. 12 However, the PK and tolerability of GSK1322322 after single or repeat dosing with elderly volunteers were similar to those observed with younger volunteers in this study. Therefore, GSK1322322 may be used to treat elderly patients without the need for any dose adjustments.
GSK1322322 administered over 10 days of continuous dosing was generally well tolerated. All AEs were mild or moderate in intensity in this study and no trends in AEs related to dose were observed. The most frequently reported AEs in this study were headache, somnolence, upper respiratory tract infection and musculoskeletal pain. It is noteworthy that somnolence was only reported when midazolam was given alone or when coadministered with GSK1322322. GSK1322322 was well tolerated from a gastrointestinal perspective as gastrointestinalrelated AEs were uncommon in this study and did not prevent volunteers from completing a 10 day course of twice-daily dosing. Overall, 10% (4 of 40) and 12% (1 of 8) of volunteers on GSK1322322 and placebo, respectively, had elevations in ALT in this study. All elevations in ALT associated with the study drug occurred within 5 -7 days of repeat dosing and were asymptomatic and fully reversible upon cessation of drug treatment.
Results from this and other Phase 1 PK studies show favourable PK and safety profiles of GSK1322322. However, the trial described herein was conducted with a small number of healthy volunteers per dose group, thus limiting the generalizability of these results and prompting the need for further evaluation of GSK1322322 in clinical studies. With the novel mechanism of action of GSK1322322 providing targeted antibacterial activity against multidrug-resistant community respiratory and skin pathogens and the promising PK and safety data observed to date, CVw, within-volunteer coefficient of variation; Ro, accumulation ratio; Rs, time invariance ratio. Repeat-dose safety and pharmacokinetics of GSK1322322 a novel peptide deformylase inhibitor, in a Haemophilus influenzae and Ae 0 -12 (AM), total amount of GSK1322322 excreted during 12 h after AM dosing; Ae 0 -12 (PM), total amount of GSK1322322 excreted during 12 h after PM dosing; Ae 0 -24 , total amount of GSK1322322 excreted from time 0 to 24 h over two dosing intervals; CVb, between-volunteer coefficient of variation.
The results are presented as mean (CVb, %). The results are presented as n (%).
a Occurring in at least four volunteers overall.
Naderer et al.
